We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Novavax Inc | NASDAQ:NVAX | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.139 | 3.52% | 4.089 | 3.96 | 4.09 | 4.13 | 3.92 | 3.97 | 3,021,805 | 00:55:01 |
Conference call details are as follows:
Date: | November 10, 2020 |
Time: | 4:30 p.m. U.S. Eastern Time (ET) |
Dial-in number: | (877) 212-6076 (Domestic) or (707) 287-9331 (International) |
Conference ID: | 1376583 |
Webcast: | www.novavax.com, “For Investors”/ “Events” |
Conference call webcast replay: | |
Dates: | Starting at 7:30 p.m. ET, November 10, 2020 until 7:30 p.m. ET November 17, 2020 |
Dial-in number: | (855) 859-2056 (Domestic) or (404) 537-3406 (International) |
Conference ID: | 1376583 |
Webcast: | www.novavax.com, “For Investors”/ “Events” until 11/17/2020 |
About Novavax
Novavax, Inc. (Nasdaq: NVAX) is a late-stage biotechnology company that promotes improved health globally through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases. Novavax is currently conducting multiple clinical trials for NVX-CoV2373, its vaccine candidate against the virus that causes COVID-19, including a pivotal Phase 3 clinical trial in the United Kingdom to evaluate the efficacy, safety and immunogenicity in individuals aged 18-84 years of age. NanoFlu™, its quadrivalent influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase 3 clinical trial in older adults. Both candidate vaccines incorporate Novavax’ proprietary saponin-based Matrix-M™ adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies. Novavax is a leading innovator of recombinant vaccines; its proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles in order to address urgent global health needs.
For more information, visit www.novavax.com and connect with us on Twitter and LinkedIn.
Contacts: InvestorsErika Trahanir@novavax.com240-268-2022
MediaBrandzone/KOGS CommunicationEdna Kaplankaplan@kogspr.com617-974-8659
1 Year Novavax Chart |
1 Month Novavax Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions